Pfizer loses closely watched court case on kickbacks and subsidizing drugs
A New York district court on Thursday knocked back Pfizer’s plan to subsidize the cost of one of its rare disease drugs for some Medicare beneficiaries.
Pfizer had attempted to convince the court that it should be able to help patients overcome a financial barrier to obtain appropriately prescribed medication they desperately need, which in this case was the company’s rare disease drug tafamidis, which comes with a $225,000 list price for a single year’s supply.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.